| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.9 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | -0.0054 | 0.9 |